Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory R Pond

Showing results (91-100 of 255) with videos related to

Pageof 26
Sort By:
BMC Cancer|November 10, 2006
Barriers in phase I cancer clinical trials referrals and enrollment: five-year experience at the Princess Margaret HospitalJeremy Ho, Gregory R Pond, Colin Newman, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 6, 2018
Association of Metformin with Breast Cancer Incidence and Mortality in Patients with Type II Diabetes: A GRADE-Assessed Systematic Review and Meta-analysisGrace H Tang, Meloja Satkunam, Gregory R Pond, et al.
European Journal of Cancer (Oxford, England : 1990)|March 3, 2015
Influence of censoring on conclusions of trials for women with metastatic breast cancerArnoud J Templeton, Olga Ace, Eitan Amir, et al.
Journal of Bone Oncology|November 19, 2015
Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-studyChristina L Addison, Gregory R Pond, Brandy Cochrane, et al.
International Journal of Surgical Oncology|February 17, 2015
Evaluating the feasibility of performing window of opportunity trials in breast cancerAngel Arnaout, Susan Robertson, Iryna Kuchuk, et al.
American Journal of Hematology|May 16, 2023
Socioeconomic marginalization and health outcomes in newly diagnosed multiple myeloma: A population-based cohort studyAlissa Visram, Hsien Seow, Mark A Fiala, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2008
Improving the quality of abstract reporting for phase I cancer trialsElizabeth L Strevel, Nicole G Chau, Gregory R Pond, et al.
Journal of Geriatric Oncology|October 28, 2020
Disparities in treatment patterns and outcomes among younger and older adults with newly diagnosed multiple myeloma: A population-based studyHira S Mian, Hsien Seow, Tanya M Wildes, et al.
Springerplus|October 22, 2014
Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastasesChristina L Addison, Gregory R Pond, Huijun Zhao, et al.
Current Oncology (Toronto, Ont.)|May 26, 2026
Assessment of Risks and Outcomes of Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease in Allogeneic Stem Cell Transplant Recipients Including Potentially Undiagnosed Cases-A Multicenter Canadian StudyEmily Trus, Alexander Ruzic, Ram Vasudevan Nampoothiri, et al.
Pageof 26

Showing results (91-100 of 255) with videos related to

Sort By:
Pageof 26
BMC Cancer|November 10, 2006
Barriers in phase I cancer clinical trials referrals and enrollment: five-year experience at the Princess Margaret HospitalJeremy Ho, Gregory R Pond, Colin Newman, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 6, 2018
Association of Metformin with Breast Cancer Incidence and Mortality in Patients with Type II Diabetes: A GRADE-Assessed Systematic Review and Meta-analysisGrace H Tang, Meloja Satkunam, Gregory R Pond, et al.
European Journal of Cancer (Oxford, England : 1990)|March 3, 2015
Influence of censoring on conclusions of trials for women with metastatic breast cancerArnoud J Templeton, Olga Ace, Eitan Amir, et al.
Journal of Bone Oncology|November 19, 2015
Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-studyChristina L Addison, Gregory R Pond, Brandy Cochrane, et al.
International Journal of Surgical Oncology|February 17, 2015
Evaluating the feasibility of performing window of opportunity trials in breast cancerAngel Arnaout, Susan Robertson, Iryna Kuchuk, et al.
American Journal of Hematology|May 16, 2023
Socioeconomic marginalization and health outcomes in newly diagnosed multiple myeloma: A population-based cohort studyAlissa Visram, Hsien Seow, Mark A Fiala, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2008
Improving the quality of abstract reporting for phase I cancer trialsElizabeth L Strevel, Nicole G Chau, Gregory R Pond, et al.
Journal of Geriatric Oncology|October 28, 2020
Disparities in treatment patterns and outcomes among younger and older adults with newly diagnosed multiple myeloma: A population-based studyHira S Mian, Hsien Seow, Tanya M Wildes, et al.
Springerplus|October 22, 2014
Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastasesChristina L Addison, Gregory R Pond, Huijun Zhao, et al.
Current Oncology (Toronto, Ont.)|May 26, 2026
Assessment of Risks and Outcomes of Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease in Allogeneic Stem Cell Transplant Recipients Including Potentially Undiagnosed Cases-A Multicenter Canadian StudyEmily Trus, Alexander Ruzic, Ram Vasudevan Nampoothiri, et al.
Pageof 26